Antitumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21 in melanomatous mouse

Immunologic Research

Volumn 52, Issue 3, 2012, Pages 240-249

  He, Xiangfeng ^a   Wang, Jing ^a   Zhao, Fengshu ^a   Yu, Fangliu ^a   Chen, Dengyu ^a   Cai, Kai ^a   Yang, Cuiping ^a   Chen, Junsong ^a   Dou, Jun ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

6 kDa early secreted antigenic target; Glycosylphosphatidylinositol; Interleukin 21; Melanoma; Tumor vaccine

Indexed keywords

CANCER VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; GLYCOSYLPHOSPHATIDYLINOSITOL; INTERLEUKIN 21; MEMBRANE PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ZINC FINGER E BOX BINDING HOMEOBOX 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; LUNG NODULE; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; INTERFERON-GAMMA; INTERLEUKINS; MELANOMA; MICE; TRANSFORMING GROWTH FACTOR BETA; VACCINATION;

EID: 84864280323     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-012-8332-4     Document Type: Article

References (36)

1. Tanaka A, Jensen JD, Prado R, Riemann H, Shellman YG, Norris DA. Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma. Gene Ther. 2011;18:827-34.
2. Asemissen AM, Brossart P. Vaccination strategies in patients with renal cell carcinoma. Cancer Immunol Immunother. 2009; 58:1169-74.
3. Fengshu Z, Jun D, Xiangfeng H, Chu LL, Hu WH, Yu FL. Enhancing therapy of B16F10 melanoma efficacy through tumor vaccine expressing GPI-anchored IL-21 and secreting GM-CSF in mouse model. Vaccine. 2010;28:2846-52.
4. Triozzi PL, Aldrich W, Achberger S, Ponnazhagan S, Alcazar O, Saunthararajah Y. Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice. Cancer Immunol Immunother. 2012; Feb 5 [Epub ahead of print].
5. Restifo NP. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr Opin Immunol. 2000;12:597-603.
6. Millington KA, Fortune SM, Low J, Garces A, Hingley-Wilson SM, Wickremasinghe M, Kon OM, Lalvani A. Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA. 2011;108:5730-5.
7. Olsen AW, Hansen PR, Holm A, Andersen P. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur J Immunol. 2000;30:1724-32.
8. Ganguly N, Giang PH, Basu SK, Mir FA, Siddiqui I, Sharma P. Mycobacterium tuberculosis 6-kDa early secreted antigenic target (ESAT-6) protein downregulates lipopolysaccharide induced c-myc expression by modulating the extracellular signal regulated kinases 1/2. BMC Immunol. 2007;8:24.
9. Ji JF, Li JH, Lillia MH. Synergistic anti-tumor effect of glycosylphosphatidylinositol- anchored IL-2 and IL-12. J Gene Med. 2004;6:777-85.
10. Naghibalhossaini F, Yoder AD, Tobi M, Stanners CP. Evolution of a tumorigenic property conferred by glycophosphatidyl-inositol membrane anchors of carcinoembryonic antigen gene family members during the primate radiation. Mol Biol Cell. 2007;18: 1366-74.
11. Butikofer P, Malherbe T, Boschung M. GPI-anchored proteins: now you see 'em, now you don't'. FASEB J. 2001;15:545-8.
12. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA. Interleukin and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408:57-63.
13. Davis ID, Skak K, Smyth MJ, Kristjansen PE, Miller DM, Sivakumar PV. Interleukin-21 signaling: functions in cancer and autoimmunity. Clin Cancer Res. 2007;13:6926-32.
14. Smyth MJ, Teng MW, Sharkey J, Wertwood JA, Haynes NM, Yagita H. Interleukin 21 enhances antibody-mediated tumor rejection. Cancer Res. 2008;68:3019-25.
15. Fengshu Z, Jun D, Jing W, Xiangfeng H, Hu WH. Investigation on the anti-tumor efficacy by expression of GPI-anchored mIL-21 on the surface of B16F10 cells in C57BL/6 mice. Immunobiology. 2010;215:89-100.
16. Thompson JA, Curti BD, Redman BG. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol. 2008;26:2034-9.
17. Frederiksen KS, Lundsgaard D, Freeman JA. IL-21 induces in vivo immune activation of NK cells and CD8(1) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother. 2008;57:1439-49.
18. Weihua H, Jing W, Jun D. Augmenting therapy of ovarian cancer efficacy by secreting IL-21 human umbilical cord blood stem cells in nude mice. Cell Transplant. 2011;20:669-80.
19. Jun D, Guobin C, Jing W. Preliminary study on mouse interleukin 21 application in tumor gene therapy. Cell Mol Immunol. 2004;1: 461-6.
20. Matsui W, Huff CA, Wang Q. Characterization of clonogenic multiple myeloma Cells. Blood. 2004;103:2332-6.
21. Dou J, Pan M, Wen P. Isolation and identification of cancer stem like cells from murine melanoma cell lines. Cell Mol Immunol. 2007;4:528-33.
22. Hervé L, Michèle F, Sylvie G. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods. 2001; 253:177-87.
23. Naeem K, Donna B, Rachel B. T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J Immunol. 2007;178:4455-65.
24. +T cells in patients with melanoma. J Immunol. 2005;175:6169-76.
25. Atanackovic D, Panse J, Hildebrandt Y. Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. Haematologica. 2011;96:1512-20.
26. Kim HS, Park HM, Park JS, Sohn HJ, Kim SG, Kim HJ, Oh ST, Kim TG. Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model. Vaccine. 2010;28:7787-96.
27. Kenichi A, Shin E, Ayumi Y. Targeting apoptotic tumor cells to FccR provides efficient and versatile vaccination against tumors by dendritic cells. J Immunol. 2003;170:1641-8.
28. Ulrike B, Jörg SC, Ulrich W. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008;9:582-9.
29. Su HY, Lai HC, Lin YW. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer. 2010;127: 555-67.
30. Berx G, Raspe E, Christofori G. Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis. 2007;24:587-97.
31. Robert S, Park SM, Andrea EM. mir-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell. 2010;38: 908-15.
32. Mikesh LM, Kumar M, Erdag G. Evaluation of molecular markers of mesenchymal phenotype in melanoma. Melanoma Res. 2010;20:485-95.
33. Jun D, Ning G. Emerging strategies for the identification and targeting of cancer stem cells. Tumor Biol. 2010;31:243-53.
34. Bracken CP, Gregory PA, Kolesnikoff N. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008;68:7846-54.
35. Ulrich W, Jörg SC, Ulrike CB, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009;12:1487-95.
36. Allen M, Jones JL. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol. 2011;223:162-76.